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Abstract 
 
An international expert consensus committee recently recommended a brief battery of tests for 
cognitive evaluation in multiple sclerosis.  The Brief International Cognitive Assessment for MS 
(BICAMS) battery includes tests of mental processing speed and memory.  Recognizing that 
resources for validation will vary internationally, the committee identified validation priorities, 
to facilitate international acceptance of BICAMS.  Practical matters pertaining to 
implementation across different languages and countries were discussed.  Five steps to achieve 
optimal psychometric validation were proposed.  In Step 1, test stimuli should be standardized 
for the target culture or language under consideration.  In Step 2, examiner instructions must be 
standardized and translated, including all information from manuals necessary for 
administration and interpretation.  In Step 3, samples of at least 65 healthy persons should be 
studied for normalization, matched to patients on demographics such as age, gender and 
education.  The objective of Step 4 is test-retest reliability, which can be investigated in a small 
sample of MS and/or healthy volunteers over 1-3 weeks.  Finally, in Step 5, criterion validity 
should be established by comparing MS and healthy controls.  At this time, preliminary studies 
are underway in a number of countries as we move forward with this international assessment 
tool for cognition in MS. 
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Background 
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system, causing 
demyelination and neurodegeneration in most patients.
1,2
  As would be expected in such a 
disease with prominent cerebral pathology, a substantial number
3-5
 of MS patients are 
compromised neuropsychologically.  In recently diagnosed or benign course patients, the 
incidence of cognitive impairment ranges from 20-40%.
5,6
  In clinic based samples where 
secondary progressive course is more common, roughly 50-60% of patients are affected.
4
   
Neuropsychological (NP) testing provides quantification of cognition, and is used 
clinically to diagnose impairment and to inform medical and behavioral treatment decisions.
7
  
Two descriptors, psychometric or neuropsychological tests, are often used inter-changeably to 
describe the cognitive testing procedures used with MS patients.8  Psychometric tests are 
standardized, behavioral measures of mental phenomena.  They measure many domains of 
mental function, including psychomotor speed and dexterity, personality or psychopathology 
[via standardized questionnaires or surveys], intelligence, memory and other aspects of 
cognitive processing [eg attention, language, executive function].   
The term neuropsychological test conveys the idea that the psychometric test result is 
relevant for conclusions pertaining to cerebral function.  Neuropsychological tests are used to 
examine brain-injured patients or to study hypotheses in neuroscience.  A deficient 
neuropsychological test value is often judged to be indicative of cerebral dysfunction.  The 
Wechsler Adult Intelligence Scale (WAIS)
9
 is a classic example of a psychometric test of 
intelligence.  It has carefully standardized instructions, scoring criteria, extensive age-based 
normative data, and information derived from extensive research concerning reliability and 
validity.  It can also be construed as a neuropsychological test [especially nonverbal 
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components] because there are extensive data that show its relationship with cognitive aging, 
dementia, and other changes in cerebral status.   
Psychometric data regarding normal performance, test reliability and the validity of test 
interpretation are necessary for accurate application of NP testing.
10
  Most tests in common use 
are carefully standardized such that the same instructions, stimuli and marking criteria are used 
by all examiners.  Most often, high test-retest reliability is emphasized in order to avoid error in 
repeat testing circumstances.  Unfortunately, alternate test versions and normative data are not 
available for some NP tests in all languages and cultures.  In addition, many centers lack 
expertise in psychometrics and NP test interpretation. 
The Brief International Cognitive Assessment for MS (BICAMS) initiative was undertaken 
to recommend a brief, cognitive assessment for MS that is optimized for small centers, with 
perhaps one or few staff members, who may not have NP training.
11
  BICAMS was particularly 
focused on international use, to facilitate comparison across settings.  An expert committee of 
twelve neurologists and neuropsychologists representing the main cultural groups that have so 
far contributed extensive data about cognitive dysfunction in MS was convened.  The opinions 
generated from the meeting are published elsewhere.
11
  In brief, the panel recommended one 
particular test with high reliability and good sensitivity, the Rao
12
 adaptation of the Symbol Digit 
Modalities Test (SDMT).
13
  Consensus was also achieved on optimal measures for learning and 
memory in MS patients, time permitting: the initial learning trials of the second edition of the 
California Verbal Learning Test (CVLT2)
14
 and the revised Brief Visuospatial Memory Test 
(BVMTR).
15
     
In order to facilitate international implementation of the BICAMS assessment, multiple 
translations are needed, as well as psychometric research to insure the reliability and validity of 
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new test forms.  With this in mind, a second conference was held to develop consensus on a 
BICAMS validation protocol. 
 
Brief International Cognitive Assessment for MS (BICAMS) Description 
The SDMT
13
 presents a series of nine symbols, each paired with a single digit in a key at the top 
of a standard sheet of paper.  An adapted version of the test is presented in Figure 1.  Patients 
are asked to voice the digit associated with each symbol as rapidly as possible for 90 sec.  There 
is a single outcome measure – the number correct over the 90 sec time span.   
The auditory/verbal learning test is the CVLT2.
16
  The test begins with the examiner 
reading a list of 16 words [Figure 2].  Patients listen to the list and report as many of the items as 
possible.  There is no instruction as to the order in which items are recalled.  After recall is 
recorded, the entire list is read again followed by a second attempt at recall.  Altogether, there 
are five learning trials.  The reader will note that the 16-item list [see faux example in Figure 2] 
has words that conform to four semantic categories, in this case sports, vegetables, clothes, and 
tools.  Some subjects will recall items in a grouped fashion, and others may recall the list in serial 
order.  There are many variables of recall available in the CVLT2, as a second list is presented, 
and after 25 min there is a delayed recall trial as well as a yes/no recognition memory task.  The 
BICAMS panel noted that few studies have shown incremental validity with these measures, as 
the total number of recalled items over the five learning trials is most sensitive.
17
   
Visual/spatial memory is assessed in BICAMS using the BVMTR.
18
  In this test, six 
abstract designs [Figure 3] are presented for 10 sec.  The display is removed from view and 
patients render the stimuli via pencil on paper manual responses.  Each design receives from 0 
to 2 points representing accuracy and location.  Thus, scores range from 0 to 12.  There are 
three learning trials, and the primary outcome measure is the total number of points earned 
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over the three learning trials.  Because there is little evidence that the delayed recall trial adds 
to discriminant validity in MS, 
4,19
 as in the MATRICS consensus battery,
20
 only the initial learning 
trials are recommended for BICAMS.     
 
Conference Process 
 
Having already decided on the core [SDMT] and ancillary memory tests [CVLT2, BVMTR], the 
focus of the conference was on a BICAMS psychometric validation protocol.  The committee 
reviewed basic psychometric standards from the literature
10,21-26
 that are widely accepted for 
validation of behavioral or psychological outcome measures.  Recognizing that economic 
resources for validation will vary across country and region, the committee discussed priorities 
for validation, that is, those aspects of research design that would enable empirical appraisal of 
core psychometrics that may engender confidence and wide application of BICAMS.  Following 
consensus on these central components, it was noted that most of the psychometric evidence 
relating to the BICAMS tests relies on US samples and discussion shifted to practical matters 
pertaining to implementation across different languages and countries.   
 
Psychometric Standards   
Standardization.  The first step in the development of any test is to ensure that test stimuli and 
administration procedures have good face validity and consistent stimulus presentation.  While 
this can be a painstaking process during the initial phases of psychometric test development, the 
work is already done for the tests that were selected for BICAMS.  The SDMT, CVLT2 and BVMTR 
stimuli are well established and are readily mass produced using digital and print technology.  
Examiners can be easily trained to use standardized instructions, more or less verbatim, to 
enhance reliability across settings.  The BICAMS tests are adequate in this regard. 
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Normalization of Raw Scores.  Normative data are of course essential for the clinical 
application of psychometric, neuropsychological tests.  Acquiring normative data can be an 
expensive endeavor.  For example, the recently revised US normative data for BVMTR has a 
sample size of 588.
27
  These data were fairly recently acquired and are judged by the BICAMS 
committee to be current.   
Normalization data for SDMT are more complicated.  The manual based norms date to 
1982, raising the spectre of cohort effects [ie gradual shift upward over time] or poor 
generalizablity to patients and controls in the present day.  Benedict et al published normative 
data on the MACFIMS battery, which includes the SDMT, in 2006
4
 and 2010,
28
 using US healthy 
samples numbering 56 and 120 respectively.  These are controlled research studies with 
applicability largely restricted to clinicians treating MS patients.  A potential problem is that 
normative data from one region [North Eastern USA in this case] may result in interpretive error 
when applied to raw test scores derived from a different culture, language, region or country.   
Reliability.  By reliability we mean the degree to which there is error when using the 
same instrument across settings, examiners, etc.  It is perhaps the most critical psychometric 
criterion - if the test is unreliable, there is little confidence in the accuracy of the outcome.  Of 
the various forms of reliability, the panel decided that test-retest reliability has the highest 
priority and is most relevant for future BICAMS validation.  The coefficient of variation can be 
used in very small samples to determine the extent to which changes in mean values outweigh 
the variance in test scores.
29
  A more valid measure of test-retest reliability is the Pearson 
correlation coefficient.
30
   Most commonly, a brief test-retest interval ranging from 1-3 weeks is 
employed.  For most purposes, r values for test-retest correlation are considered adequate if > 
0.70 and good if > 0.80.23   
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The SDMT has particularly high test-retest reliability.  In one US study of MS patients the 
test-retest r value was 0.97.  In a US study repeating the test over six monthly sessions, r values 
approximated 0.80 for healthy controls and 0.90 for MS patients.  Acceptable test-retest 
reliability [CVLT2 = 0.78; BVMTR = 0.91] was found in a well controlled investigation with US MS 
patients.
31
 
Validity.  Rather than accuracy, validity refers to the meaning of a test score.  There are 
multiple aspects of validity in psychometric science.  Does a low score, for example, represent 
the presence of neuropsychological dysfunction, a particular disease state such as MS, a high 
likelihood of brain atrophy or some other marker of cerebral involvement, or perhaps an 
increased risk of failing at work?  Correlations between test scores and other measures [ie 
validity coefficient r] and comparing differences in the performance from specified samples [eg, 
MS vs controls; employed vs disabled MS patients] are common methods of investigation.   
The BICAMS committee decided that the most important aspect of validity for clinical 
purposes is criterion-related validity, most notably differentiating MS patients from healthy 
controls.  All of the BICAMS tests discriminate well with SDMT most often the most sensitive 
measure in NP batteries.
4,19
 
A more difficult endeavor is to establish the ecological or predictive validity of a 
psychometric test.
32
  Neuropsychological testing is correlated with a wide range of activities of 
daily living in MS,
33-40
 as well as work disability.
41-44
  The BICAMS tests are correlated with 
vocational outcomes
4,45-47
 and recently job loss was associated with specific decline of 4-5 points 
on SDMT.
48
  More such research is needed in order to clearly establish thresholds for clinically 
meaningful changes for the BICAMS measures. 
Alternate Test Forms.  When NP tests are repeated in healthy volunteers or stable MS 
patients, performance often improves for two reasons: item-specific or task-specific learning.49  
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The former refers to the learning of, or memory for, specific test stimuli. For example, on the 
CVLT2, one might remember specific words from one testing session to the next.  Indeed, on a 
similar test, the 1
st
 trial recall was similar to the delayed recall trial of the same test 
administered two weeks earlier, but only when the same list was repeated.
49
  Test- or task-
specific learning refers to the benefit of performing the same behavioral procedure successively, 
even if the to-be-remembered stimuli are altered.  For example, one could possibly learn to 
label BVMTR figures verbally, a strategy that may carry over to the next session, despite 
presenting different figures.  While both item- and task-specific practice likely play a role in 
retest effects, in MS, we
31
 have found that changing  stimuli reduces practice effects on memory 
tests such as the CVLT2 and BVMTR.   
The SDMT was originally published with one test form.  Alternate forms were generated 
by Rao and colleagues,
3,12
 but in the only work examining inter-form equivalence,
50
 there was 
little support for the forms being equivalent.  Recently, two new forms were created and found 
to be equivalent to the standard form.
51
  There are two forms for the CVLT2.  In the CVLT2 test 
manual, the normative data are very similar for each form, and the forms yielded similar data in 
a test-retest within-subjects design.
31
  There is strong support for inter-form reliability for the 
BVMTR.
20,31,49,52-54
  
 
Consensus Opinion: The BICAMS Validation Protocol    
The above list of psychometric criteria is not intended to be complete or comprehensive.  The 
selected criteria are judged to be most essential in the test development process.  As we move 
forward with implementing BICAMS internationally, each of these criteria may be difficult to 
achieve in other languages and cultures.  In this section, we describe the suggested, core 
validation process, highlighting special considerations for each of the BICAMS measures.  
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Table 1 
Manner in which BICAMS measures meet psychometric criteria in samples with English as a first 
language. 
 
 SDMT CVLT2 BVMTR 
Standardization  Smith 1982 Teat 
Manual 
Delis 2000 Test Manual Benedict 1997 Test 
Manual 
Normalization Parmenter 2010. Peer 
review journal article 
Delis 2000 Test Manual Benedict 2005 Test 
Manual 
Reliability I: Test-
Retest 
Benedict 2005  r = 0.91 Benedict 2005  r = 0.80 Benedict 2005 r = 0.91 
Reliability II: Alternate 
Form 
Rao 1991. Benedict 
2012. Good 
Delis 2000.  Fair Benedict 1996. Good 
Validity I: Criterion 
Related 
Many Studies. Good Many Studies. Good Many Studies. Good 
Validity II: Clinically 
Meaningful Change 
Morrow 2010. Fair No or Little Data No or Little Data 
 
 
The BICAMS tests were selected, in part, due to extant validation findings and thus it is not 
surprising that they hold up well to psychometric scrutiny.  Table 1 summarizes what we know 
about the current English versions of BICAMS.  Note that the tests are good on the most primary 
criteria, involving standardization, normalization, test-retest reliability and criterion-related 
validity.  More variable data are available pertaining to alternate forms and predicting clinically 
meaning changes over time.  Looking forward, as summarized in the text box below, we 
envisage five steps in future validation protocols in populations for whom English is not the first 
language.   
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 Step 1, Standardization and Translation of Test Stimuli. For visual stimuli, 
determine if there are any semantic associations to stimuli in the culture or 
language under consideration.  For CVLT2 must match new words on word 
frequency and appropriate similarity of meaning. If these parameters cannot be 
applied scientifically, then expert review and performance on test by appropriate 
participants will be utilized to assess translation.  
 Step 2, Standardization and Translation of Test Instructions.  All information from 
the test manual necessary for administration and interpretation must be 
translated, back translated, and checked for errors. Where possible the 
translated instructions should be validated against expected participant 
performance in terms of accuracy and error profile. Step 4 will also contribute to 
the accuracy of the test instructions. 
 Step 3, Normalization.  Large samples of 150 or more healthy persons are needed 
for data applicable to persons of all ages and diverse ethnicity.  The minimum 
sample size is 65 healthy volunteers, provided they are group matched on 
demographics to either a concurrent MS sample, or matched to samples in other 
published descriptive MS studies. Where possible, the distribution of test scores 
and error profile of the normalization sample should be examined and compared 
to published distributions from other language groups.  
 Step 4, Test-Retest Reliability.  Assessment of this criterion can be achieved by 
evaluating an MS and/or healthy volunteer sample on two occasions separated 
by 1-3 weeks.  This is the gold standard separation where the question is only 
test reliability, controlling for maturation effects.  A Pearson’s correlation 
coefficient >0.70 will usually be required. 
 Step 5, Criterion-Related Validity.  This step can be pursued in conjunction with 
Step 3, in that an MS sample can be compared to a healthy control group that 
also serves for normalization.  To determine if a new Italian BVMTR is sensitive to 
MS disease state, for example, compare 50 patients to the healthy controls in 
Step 3.  After the study, the investigator adds another 35 healthy volunteers to 
round out the normalization sample. 
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Preliminary work in Step 1 will be needed to maximize standardization while remaining 
true to the meaning of the original version, where possible.  The extant SDMT stimuli are 
deemed adequate for international use, at least for cultures where Arabic numerals are in 
common use.  One consideration is the pronounciation of numbers which may vary from 
monosyllabic to polysyllabic utterances [eg one in English and nueve in Spanish], or be simply 
longer in others [eg üheksa in Estonian].  Rarely, the meaning of the SDMT and BVMTR symbols 
could become important.  These stimuli have no semantic meaning in English but could 
conceivably have meaning in some cultures.  Like the SDMT, the BVMTR test stimuli are 
adequate for international application.   
The CVLT2 is of course entirely another matter.  Here, precise translation necessitates as 
close approximation of the English words, while maintaining word frequency in the target 
language, semantic relationships among the target words, orthography, and alike.  As noted 
above, in some languages this could mean a very arduous process.  The BICAMS committee 
agreed that in some countries, another, simple, auditory word-list learning test could replace 
CVLT2, provided that the procedure is in the common format – that is reading the list on each 
learning trial and including at least three learning trials.  Some English language examples are 
the Rey Auditory Verbal Learning Test55 and the revised Hopkins Verbal Learning Test.56,57   
All BICAMS tests must re-standardize the administration and scoring instructions in the 
new language.  The time required for Step 2 will depend on the specific test and technical 
support available.  The patient instructions for SDMT are brief, and there is minimal instruction 
necessary for scoring the test in the standardized manner.  In contrast, the scoring aspects of 
the BVMTR manual are quite detailed.  Patient responses could be delivered to another party 
and scored blindly in lieu of translating the entire scoring sections of the manual.   
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In Step 3, a sample of at least 65 healthy volunteers must be studied with the new 
BICAMS to develop normative data in the native language.  This minimum sample size should 
provide enough power to detect a medium effect size in a two-group [eg MS vs controls] 
comparison.  Unless a larger sample is available, the normalization sample should be group 
matched to population studies of MS patients in terms of demographic characteristics.  Linear 
regression approaches can be employed to extend the applicability of the data to demographics 
that are not fully represented in the database.   
Test-retest reliability can be assessed in both patients and controls by a repeat testing 
session 1-3 weeks after baseline [Step 4].  While both samples are of interest, the panel believes 
that reliability in MS is more important than in healthy volunteers.  In order to assess criterion-
related validity [Step 5], the controls must be compared to MS patients, with control for 
demographics.  If Steps 1 and 2 have been completed effectively, all BICAMS variables should 
discriminate the groups significantly, with d values > 0.5.  Studies to determine the validity of 
BICAMS in distinguishing MS populations from healthy controls will need to be carefully 
constructed, because the criteria of diagnosis of MS adopted may vary among countries.
58
  It 
may be necessary for published data to be segmented to allow comparison with MS samples 
from other language groups and the BICAMS committee will facilitate this wherever possible. 
Finally, other psychometric considerations include inter-rater reliability, alternate forms, 
and various forms of convergent and discriminant validity.  These are not deemed essential, but 
potentially valuable.  For example, does BICAMS predict vocational outcomes?  Are low BICAMS 
scores associated with brain atrophy?  Alternate form reliability work has already been 
commenced by some members of the BICAMS committee.  
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Conclusion 
The Brief International Cognitive Assessment for MS (BICAMS) initiative was undertaken to 
recommend a brief, cognitive assessment for MS that can be utilized internationally, in small 
centers, with perhaps one or few staff members, who may or may not have formal 
neuropsychological training.  Consensus was earlier achieved regarding the BICAMS tests, with 
special consideration for SDMT, and supplementation by CVLT2 and BVMTR, time permitting.  
Research is needed to validate BICAMS where English is not the first language.  In this article, we 
have summarized a second consensus opinion which offers a process by which BICAMS can be 
validated in other languages.  Research projects pursuing some of the aims described herein are 
underway. 
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Figure 2 
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Figure 3 
 
 
 
 
 
 
 
 
 
Benedict et al, Cognition and MS   -   20 
 
  
 
References 
 
1. Hauser SL, Oksenberg JR, Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, 
inflammation, and neurodegeneration. Neuron 2006;52:61-76. 
2. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev 
Neurosci 2008;31:247-69. 
3. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. 
Frequency, patterns, and prediction. Neurology 1991;41:685-91. 
4. Benedict RHB, Cookfair D, Gavett R, et al. Validity of the Minimal Assessment of Cognitive 
Function in Multiple Sclerosis (MACFIMS). Journal of the International Neuropsychological Society 
2006;12:549-58. 
5. Patti F, Amato M, Trojano M, et al. Cognitive impairment and its relation with disease measures 
in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive 
Impairment in Multiple Sclerosis (COGIMUS) study. Mult Scler 2009;15:779-88. 
6. Glanz BI, Holland CM, Gauthier SA, et al. Cognitive dysfunction in patients with clinically isolated 
syndromes or newly diagnosed multiple sclerosis. Mult Scler 2007;13:1004-10. 
7. Benedict RHB. Integrating cognitive function screening and assessment into the routine care of 
multiple sclerosis patients. CNS Spectrums 2005;in press. 
8. Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple 
sclerosis. Nat Rev Neurol 2011. 
9. Wechsler D. Wechsler Adult Intelligence Scale, Fourth Edition. New York: Pearson; 2008. 
10. Lezak M. Neuropsychological Assessment. 2nd ed. New York: Oxford University Press; 1995. 
11. Langdon DW, Amato MP, Boringa J, et al. Recommendations for a Brief International Cognitive 
Assessment for Multiple Sclerosis (BICAMS). Multiple Sclerosis Journal;in press. 
12. Rao SM. A Manual for the Brief, Repeatable Battery of Neuropsychological Tests in Multiple 
Sclerosis: National Multiple Sclerosis Society; 1991. 
13. Smith A. Symbol digit modalities test: Manual. Los Angeles: Western Psychological Services; 
1982. 
14. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test Manual: Second Edition, 
Adult Version. San Antonio, TX: Psychological Corporation; 2000. 
15. Benedict RHB. Brief Visuospatial Memory Test - Revised: Professional Manual. Odessa, Floriday: 
Psychological Assessment Resources, Inc.; 1997. 
16. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test manual: Second edition,  
Adult version. San Antonio, TX: Psychological Corporation.; 2000. 
Benedict et al, Cognition and MS   -   21 
 
17. Stegen S, Stepanov I, Cookfair D, et al. Validity of the California Verbal Learning Test-II in Multiple 
Sclerosis. Clin Neuropsychol 2009:1-14. 
18. Benedict R. Brief Visuospatial Memory Test-Revised: Professional manual. Odessa, Florida: 
Psychological Assessment Resources; 1997. 
19. Strober L, Englert J, Munschauer F, Weinstock-Guttman B, Rao S, Benedict RH. Sensitivity of 
conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological 
Battery and the Minimal Assessment of Cognitive Function in MS. Mult Scler 2009;15:1077-84. 
20. Buchanan RW, Davis M, Goff D, et al. A Summary of the FDA-NIMH-MATRICS Workshop on 
Clinical Trial Design for Neurocognitive Drugs for Schizophrenia. Schizophrenia Bulletin 2005;31:5-19. 
21. Benton AL, Sivan AB, Hamsher K, Varney NR, Spreen O. Contributions to Neuropsychological 
Assessment. Second ed. New York: Oxford University Press; 1994. 
22. Spreen O, Strauss E. A compendium of neuropsychological tests: Administration, norms, and 
commentary. Second ed. New York: Oxford University Press; 1998. 
23. Anastasi A. Psychological Testing. 6th ed: Macmillan Publishing Company; 1988. 
24. Benedict RHB, Fischer JS, Archibald CJ, et al. Minimal Neuropsychological Assessment of MS 
Patients: A Consensus Approach. Clinical Neuropsychologist 2002;16:381-97. 
25. Amato MP, Zipoli V, Portaccio E. Mulitple-sclerosis related cognitive changes: A review of cross-
sectional and longitudinal studies. Journal of the Neurological Sciences 2006;245:41-6. 
26. Camp SJ, Thompson AJ, Langdon DW. A new test of memory for multiple sclerosis I: format 
development and stimuli design. Mult Scler 2001;7:255-62. 
27. Benedict RHB, Brandt J. Hopkins Verbal Learning Test Revised and Brief Visuospatial Memory 
Test Revised: Professional Manual Supplement. Odessa, Fl.: Psychological Assessment Resources, Inc.; 
2007. 
28. Parmenter BA, Testa SM, Schretlen DJ, Weinstock-Guttman B, Benedict RHB. The utility of 
regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis 
(MACFIMS). Journal of the International Neuropsychological Society 2010;16:6-16. 
29. Horsfield MA, Rovaris M, Rocca MA, et al. Whole-brain atrophy in multiple sclerosis measured by 
two segmentation processes from various MRI sequences. Journal of the Neurological Sciences 
2003;216:169-77. 
30. Cohen J, Cohen P. Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences, 
Second Edition. Hillsdale, NJ: Lawrence Erlbaum; 1983. 
31. Benedict RHB. Effects of using same vs. alternate form memory tests in short-interval, repeated 
assessment in multiple sclerosis. Journal of the International Neuropsychological Society 2005;11:727-36. 
32. King MT. A point of minimal important difference (MID): a critique of terminology and methods. 
Expert Rev Pharmacoecon Outcomes Res 2011;11:171-84. 
33. Langdon DW, Thompson AJ. Multiple sclerosis: a preliminary study of selected variables affecting 
rehabilitation outcome. Multiple Sclerosis 1999;5:94-100. 
Benedict et al, Cognition and MS   -   22 
 
34. Amato MP, Ponziani G, Pracucci G, Bracco L, Siracusa G, Amaducci L. Cognitive impairment in 
early-onset multiple sclerosis: Pattern, predictors, and impact on everyday life in a 4-year follow-up. 
Archives of Neurology 1995;52:168-72. 
35. Jean VM, Paul RH, Beatty WW. Psychological and neuropsychological predictors of coping 
patterns by patients with multiple sclerosis. Journal of Clinical Psychology 1999;55:21-6. 
36. Schultheis MT, Garay E, Millis SR, DeLuca J. Motor vehicle crashes and violations among drivers 
with multiple sclerosis. Archives of Physical Medicine & Rehabilitation 2002;83:1175-8. 
37. Goverover Y, Kalmar J, Gaudino-Goering E, et al. The relation between subjective and objective 
measures of everyday life activities in persons with multiple sclerosis. Archives of Physical Medicine & 
Rehabilitation 2005;86:2303-8. 
38. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life in multiple sclerosis: measuring the 
disease effects more broadly. Neurology 1999;53:1098-103. 
39. Goverover Y, Genova HM, Hillary FG, DeLuca J. The relationship between neuropsychological 
measures and the Timed Instrumental Activities of Daily Living task in multiple sclerosis. Multiple Sclerosis 
2007;13:636-44. 
40. Schultheis MT, Weisser V, Ang J, et al. Examining the relationship between cognition and driving 
performance in multiple sclerosis. Arch Phys Med Rehabil 2010;91:465-73. 
41. Beatty WW, Goretti B, Siracusa G, Zipoli V, Portaccio E, Amato MP. Changes in 
neuropsychological test performance over the workday in multiple sclerosis. Clinical Neuropsychologist 
2003;17:551-60. 
42. Goretti B, Portaccio E, Zipoli V, Razzolini L, Amato MP. Coping strategies, cognitive impairment, 
psychological variables and their relationship with quality of life in multiple sclerosis. Neurol Sci 
2010;31:S227-30. 
43. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unveragt F. Cognitive dysfunction in multiple 
sclerosis. II. Impact on employment and social functioning. Neurology 1991;41:692-6. 
44. LaRocca NG, Kalb RC, Gregg K. A program to facilitate retention of employment among persons 
with multiple sclerosis. Work 1996;7:37-46. 
45. Benedict RHB, Wahlig E, Bakshi R, et al. Predicting quality of life in multiple sclerosis: Accounting 
for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. Journal of the 
Neurological Sciences 2005:29-34. 
46. Benedict RHB, Zivadinov R. Predicting neuropsychological abnormalities in multiple sclerosis. 
Journal of the Neurological Sciences 2006;245:67-72. 
47. Parmenter BA, Zivadinov R, Kerenyi L, et al. Validity of the Wisconsin Card Sorting and Delis-
Kaplan Executive Function System (DKEFS) Sorting Tests in Multiple Sclerosis. Journal of Clinical & 
Experimental Neuropsychology 2007;29:215-23. 
48. Morrow SA, Drake AS, Zivadinov R, Munschauer F, Weinstock-Guttman B, Benedict RHB. 
Predicting loss of employment over three years in multiple sclerosis: Clinically meaningful 
cognitive decline. Clinical Neuropsychologist in press. 
Benedict et al, Cognition and MS   -   23 
 
49. Benedict RHB, Zgaljardic DJ. Practice effects during repeated administrations of memory tests 
with and without alternate forms. Journal of Clinical and Experimental Neuropsychology 1998;20:339-52. 
50. Boringa JB, Lazeron RH, Reuling IE, et al. The brief repeatable battery of neuropsychological tests: 
normative values allow application in multiple sclerosis clinical practice. Multiple Sclerosis 2001;7:263-7. 
51. Benedict RH, Smerbeck A, Parikh R, Rodgers J, Cadavid D, Erlanger D. Reliability and equivalence 
of alternate forms for the Symbol Digit Modalities Test: implications for multiple sclerosis clinical trials. 
Mult Scler 2012. 
52. Benedict RHB, Groninger L. Preliminary standardization and validation of a new visuospatial 
memory test with six alternate forms. Clinical Neuropsychologist 1995;9:11-6. 
53. Benedict RHB, Schretlen D, Groninger L, Dobraski M, Shpritz B. Revision of the Brief Visuospatial 
Memory Test: Studies of normal performance, reliability, and validity. Psychological Assessment 
1996;8:145-53. 
54. Green MF, Nuechterlein KH. The MATRICS initiative: Developing a consensus cognitive battery for 
clinical trials. Schizophrenia Research 2004;72:1-3. 
55. Rey A. L'Examen Clinique en Psychologie. Paris: Press Universitaire de France; 1964. 
56. Benedict RHB, Schretlen D, Brandt J, Groninger L. Revision of the Hopkins Verbal Learning Test: 
Reliability and normative data. Clinical Neuropsychologist 1998;12:43-55. 
57. Shapiro AM, Benedict RHB, Schretlen D, Brandt J. Construct and concurrent validity of the 
Hopkins Verbal Learning Test - Revised. Clinical Neuropsychologist 1999;13:348-58. 
58. Trojano M. Multiple sclerosis: The evolving diagnostic criteria for multiple sclerosis. Nat Rev 
Neurol 2011;7:251-2. 
 
 
